USANA Health Sciences, Inc. - 2007 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-K
Reporting Period: Fiscal year ended December 29, 2007
Business Model: USANA develops, manufactures, and distributes science-based nutritional and personal care products through a global network marketing system. The customer base consists of independent "Associates" (distributors) and "Preferred Customers" (personal use only).
Operational Change: In August 2007, the company sold its third-party contract manufacturing business to focus exclusively on its Direct Selling segment. Results from the former contract manufacturing segment are now reported as discontinued operations.
Key Financial Metrics (Fiscal Year 2007)
| Metric | 2007 Value | 2006 Value |
|---|---|---|
| Net Sales | $423.1 million | $365.2 million |
| Gross Profit | $335.3 million (79.2% margin) | $285.3 million (78.1% margin) |
| Net Earnings | $45.3 million | $41.3 million |
| Diluted EPS (Continuing Ops) | $2.67 | $2.25 |
| Operating Cash Flow | $57.2 million | $60.2 million |
| Cash and Equivalents (Year End) | $12.9 million | $27.0 million |
| Working Capital | $5.8 million | $20.8 million |
| Debt (Line of Credit) | $28.0 million outstanding | $0 outstanding |
| Associate Incentives | $170.4 million (40.3% of sales) | $146.3 million (40.1% of sales) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.9% year-over-year, driven by a 15.0% increase in active Associates (176,000 in 2007 vs. 153,000 in 2006) and the launch of operations in Malaysia in January 2007.
- Geographic Shift: While North America remains the largest market (63.1% of sales), international growth was significant. Southeast Asia/Pacific sales grew 39.3% and East Asia sales grew 31.6%.
- Liquidity Position: Cash and cash equivalents decreased by $14.2 million. This reduction was primarily due to $79.6 million spent on share repurchases and $26.3 million in capital expenditures for facility expansions in Utah and Australia.
- Debt Utilization: The company utilized its line of credit for the first time in recent years, with a $28.0 million balance at year-end to fund capital projects and share buybacks.
- Margin Expansion: Gross profit margin improved to 79.2% from 78.1%, attributed to reduced inventory scrap and lower relative freight costs.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Capital Expenditures: The company anticipates total investments in property, plant, and equipment for 2008 to be between $15 million and $20 million, primarily for the completion of the Salt Lake City headquarters expansion and the Sydney, Australia facility.
- Growth Strategy: Focus remains on recruiting and retaining Associates, expanding into new international markets, and introducing new products (e.g., MyHealthPak).
- Seasonality: The third quarter is historically the softest quarter due to summer vacations and the timing of the International Convention.
- Legal Proceedings: The company is defending against a consolidated shareholder class action lawsuit and a derivative lawsuit, both prompted by allegations made by Barry Minkow regarding the company's business model. The SEC closed an informal inquiry in January 2008 with no enforcement action recommended.
- Regulatory Environment: Network marketing is subject to intense government scrutiny. Changes in laws regarding pyramid schemes or advertising substantiation could materially affect operations.
- Associate Dependency: Sales are directly dependent on the efforts of independent Associates. High turnover or failure to recruit new Associates could adversely affect results.
- Foreign Exchange: Approximately 60% of sales are generated outside the U.S. A strengthening U.S. dollar could negatively impact reported earnings.
Investor Verification Checklist
- Associate Retention Rates: Verify the stability of the 176,000 active Associate base and the impact of the "seamless" compensation plan on retention in new markets like Malaysia.
- Capital Expenditure Completion: Monitor the completion and cost overruns of the Salt Lake City and Sydney facility expansions, which are driving current debt levels.
- Legal Resolution: Track the status of the shareholder class action and derivative lawsuits to assess potential financial liabilities or reputational damage.
- Debt Covenants: Review compliance with EBITDA and debt coverage ratio covenants on the $40 million line of credit, given the $28 million outstanding balance.
- Product Mix: Confirm the sales contribution of the new MyHealthPak product line versus traditional bottled supplements.